BALY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient buyer: the tape is still bearish (negative, expanding MACD) and near-term statistical outlook skews down (next week/month probabilities negative).", "Price is only slightly above first support (S1 14.85) and still below the pivot (15.71); risk of another leg down toward S2 (14.31) is meaningful if support fails.", "Without any Intellectia buy signals today (AI Stock Picker/SwingMax), there isn\u2019t a high-conviction timing edge to justify jumping in pre-market."]
["Trend/Momentum: MACD histogram -0.167 and negatively expanding \u2192 downside momentum is strengthening.", "RSI: RSI(6) ~24.35 \u2192 short-term oversold conditions; this can support a dead-cat bounce, but it is not a reversal confirmation by itself.", "Moving averages: converging MAs \u2192 no clear trend reversal signal; more consistent with consolidation in a bearish context.", "Key levels: Pre-market ~14.94 is just above S1 14.847. Resistance/pivot at 15.71, then R1 16.574. A sustained reclaim of 15.71 would be the first technical improvement; losing 14.85 risks a move toward S2 14.314."]
~
can attract short-covering and produce a fast bounce if 14.85 support holds.", "Gross margin improved YoY (44.21%, +4.74% YoY), showing some operating improvement beneath the headline loss.", "Project optionality (from analyst notes): continued construction/progress in Chicago and Baton Rouge; longer-dated upside optionality tied to NY license efforts and broader development initiatives.", "Next earnings catalyst: QDEC 2025 earnings on 2026-02-26 (after hours) could reset expectations if results/guide surprise positively."]
["Bearish momentum is still accelerating (MACD negative and expanding), raising the odds that support breaks rather than holds.", "Fundamentals: net loss widened YoY (Net Income -$102.9M, worse by ~58% YoY) and EPS declined to -1.70 (down ~66.7% YoY) despite revenue growth.", "Analyst risk: Barclays downgraded to Underweight with an $11 target (well below current ~15), highlighting idiosyncratic risk into 2026.", "No supportive news flow in the past week to spark a sentiment reversal; near-term drift can remain negative.", "Pattern-based outlook provided: ~40% chance of only +0.83% next day, but expected skew is negative over next week (-1.36%) and next month (-4.22%)."]
["Latest quarter: 2025/Q3.", "Revenue: $663.7M, +5.36% YoY (top-line growth is positive).", "Profitability: Net Income -$102.9M (loss widened ~58.48% YoY) and EPS -1.70 (down ~66.67% YoY) \u2192 growth is not translating into earnings.", "Margins: Gross margin 44.21%, +4.74% YoY \u2192 some operational improvement, but not enough to offset broader costs/interest/other drags implied by deeper losses."]
["Recent rating/target trend is mixed: two firms maintained Hold while sharply raising price targets (Truist to $18; Stifel to $20) after Q3 EBITDA strength/mixed quarter.", "However, the most recent notable change is negative: Barclays downgraded to Underweight with an unchanged $11 target, citing a potentially idiosyncratic 2026 backdrop for the group.", "Wall Street \u2018pros\u2019 view: upside optionality if projects/EBITDA execution improves and development catalysts (Chicago progress, licensing efforts) materialize.", "Wall Street \u2018cons\u2019 view: earnings quality and loss trajectory remain a concern; downgrade risk and execution/event risk keep conviction muted.", "Flows/checks: Hedge funds neutral; insiders neutral; no recent Congress trading data available."]
